Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07597499 · ClinicalTrials.gov registry record · NA

ANCHOR Validation Trial in High-Risk Multidisciplinary Care

A NA study, sponsored by Waymark.

Completed
Registry status
NA
Development phase
240
Enrollment target

NCT07597499 is a NA study that has completed, run by Waymark. The registered enrollment target is 240 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07597499, a NA study, has completed, sponsored by Waymark.

COMPLETED
Registry status
NA
Development phase
240 participants
Enrollment target

Study Summary

This pre-registered, pragmatic, three-arm (1:1:1) patient-level randomized controlled trial with mixed-effects analysis at the encounter level tests two questions in real high-risk multidisciplinary clinical encounters at the Waymark clinically integrated network across three U.S. states (Ohio, Washington, Virginia): (1) does adding ANCHOR - a clinical AI structural verification layer - to a Gemini 3.1 Pro-assisted supervising-physician workflow reduce the rate of clinically meaningful safety failures, compared with the same Gemini 3.1 Pro-assisted workflow without ANCHOR? (2) does the Gemini 3.1 Pro-assisted workflow itself reduce the same safety endpoint compared with unassisted standard care in which the supervising physician writes their own SOAP assessment/plan from a blank template? ANCHOR is a single-call structural verification layer combining a Logical Neural Network (Riegel et al. 2020) certificate, six specialist agents, and concept-decomposed output with PMID citation provenance. ANCHOR is physician-facing only and is used by supervising physicians, not by the multidisciplinary clinical team they oversee. The trial randomizes 240 patients 1:1:1 across the Waymark clinically integrated network over a 12-week active-enrolment window (80 per arm). Eligible patients are adults (age 18+) identified as high-risk by combined claims-based and clinical criteria. Eligible encounters span three integrated Waymark service modalities: high-risk primary care, specialty care coordination, and real-time telemedicine urgent care. The primary endpoint is a per-encounter binary composite: any of (a) failure to mention a do-not-miss diagnosis, (b) under-triage, (c) contraindicated medication recommendation, (d) failure to recommend escalation when clinically warranted; adjudicated by a blinded panel of 3 board-certified physicians with majority-of-three scoring. The primary contrast is Arm 3 (LLM+ANCHOR) versus Arm 2 (LLM with safety prompt), isolating ANCHOR's marginal c

Interventions

  • BEHAVIORAL Gemini 3.1 Pro with Safety Prompt
  • BEHAVIORAL ANCHOR Clinical AI Verification Layer (with Gemini 3.1 Pro)

Trial Details

FieldValue
Enrollment Target 240 participants
Start Date 2026-05-15
Est. Completion 2026-07-06
Phase NA

Sponsor

Waymark

2 total trials

What the Registry Record Tells You About NCT07597499

The ClinicalTrials.gov registry entry for NCT07597499 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Waymark, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Gemini 3.1 Pro with Safety Prompt is the first listed.

NCT07597499 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT07597499 about?

NCT07597499 is a clinical study titled "ANCHOR Validation Trial in High-Risk Multidisciplinary Care". This pre-registered, pragmatic, three-arm (1:1:1) patient-level randomized controlled trial with mixed-effects analysis at the encounter level tests two questions in real high-risk multidisciplinary clinical encounters at the Waymark clinically integrated network across three U.S. states (Ohio, Wash...

What is the current status of trial NCT07597499?

This trial is currently completed. It is a NA study. The enrollment target is 240 participants. The study started on 2026-05-15. Estimated completion is 2026-07-06.

What interventions are being tested in trial NCT07597499?

The interventions under investigation include: Gemini 3.1 Pro with Safety Prompt (BEHAVIORAL), ANCHOR Clinical AI Verification Layer (with Gemini 3.1 Pro) (BEHAVIORAL).

Who is sponsoring clinical trial NCT07597499?

This trial is sponsored by Waymark, which has 2 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.